BioCentury | Nov 12, 2020
Finance

Nov. 11 Quick Takes: Adagio raises $80M for COVID-19 antibody; plus venture investments for Congenica, CoImmune, Trailhead, Doer Biologics, Protomer and more

...I-IIa trials for leukemia and lymphoma.Goldman injects cash into Biocon BiologicsBiocon Ltd. (NSE:BIOCON; BSE:532523) said its Biocon...
BioCentury | Oct 13, 2020
Deals

Launched by Mazumdar-Shaw, Parmar and Mukherjee, Immuneel takes step toward $50,000 CAR T for India

...the timetable, Kiran Mazumdar-Shaw, one of Immuneel’s co-founders, told BioCentury. Shaw is executive chairperson of Biocon...
BioCentury | Oct 2, 2020
Management Tracks

Merck’s Perlmutter joins insitro’s board; plus moves at PureTech, Intra-Cellular, Arcus and more

...the board of PureTech Health plc (LSE:PRTC). Mazumdar-Shaw is the co-founder and executive chairperson of Biocon Ltd. (NSE:BIOCON...
BioCentury | Sep 1, 2020
Product Development

Aug. 31 Quick Takes: Mylan, Biocon launch cheaper insulin in U.S.; plus: AZ, bluebird, Lipocine, Amgen, AbbVie-Morphic, Polyphor-Fosun and Milestone

...Staff Writer Mylan, Biocon launch long-acting insulin biosimilar in U.S.Mylan N.V. (NASDAQ:MYL) and Biocon Ltd. (NSE:BIOCON...
...in adults with Type II diabetes and adults and children with Type I diabetes (see “Biocon...
BioCentury | Aug 1, 2020
Product Development

Will Biocon’s COVID-19 anti-inflammatory succeed where IL-6 blockers have failed?

...Alzumab itolizumab among the drugs on its COVID-19 treatment protocol. With an Indian EUA for Alzumab, Biocon...
...it to succeed where IL-6 inhibitors have failed. Mazumdar-Shaw is executive chair of Biocon Ltd. (NSE:BIOCON...
...on Friday, Tata Capital Growth Fund invested Rs2.3 billion in Biocon Biologics Ltd., valuing the Biocon...
BioCentury | Jul 14, 2020
Product Development

Immune-targeted mAb from Biocon, Equillium to enter global trials after Indian approval in COVID-19 patients

...$23.31 (731%) to $26.50 on Monday to reach a valuation of $468.6 million. Biocon Ltd. (NSE:BIOCON...
...alone, seven recovered and three died. According to Biocon, the survival benefit was statistically significant. Biocon...
...from the adaptive study (see “UK Approves Steroid” ). Sandi Wong, Assistant Editor Alzumab, itolizumab (EQ001, anti-cd6, t1h) Biocon...
BioCentury | Jun 12, 2020
Regulation

Approval of Biocon, Mylan insulin product could herald cheaper insulin in U.S.

...from Biocon and Mylan has at last gained FDA’s approval to treat diabetes. Biocon Ltd. (NSE:BIOCON...
...claims for U.S. Patent 9,526,844 held by Sanofi (Euronext:SAN; NASDAQ:SNY) covering Lantus insulin glargine (see “Biocon...
...overcome two complete response letters; the second, issued in August 2019, had cited problems at Biocon’s...
BioCentury | Mar 16, 2020
Product Development

Teva, Celltrion launch fourth U.S. Herceptin biosimilar at modest discount

...U.S. by Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN); Mylan N.V. (NASDAQ:MYL) and Biocon Ltd. (NSE:BIOCON...
...launched in January at a 22% discount. Steve Usdin, Washington Editor Teva Pharmaceutical Industries Ltd. Celltrion Inc. Genentech Inc. Roche Mylan N.V. Biocon...
BioCentury | Mar 11, 2020
Product Development

Biocon, Mylan look ahead to U.S. launch of insulin glargine as last Lantus patent falls for Sanofi

...A district court decision in favor of Biocon and Mylan sets the partners up to launch...
...held by Sanofi (Euronext:SAN; NASDAQ:SNY) covering Lantus insulin glargine. Mylan N.V. (NASDAQ:MYL) and Biocon Ltd. (NSE:BIOCON...
...average net prices for insulin and increased contributions to the Medicare Part D coverage gap. Biocon...
BioCentury | Mar 10, 2020
Politics, Policy & Law

We’ve moved on from nude women parties. The progress is much bigger than that.

...Westlake Village BioPartners in Los Angeles. Kiran Mazumdar-Shaw, chairperson and managing director of Biocon Ltd. (NSE:BIOCON...
Items per page:
1 - 10 of 443